Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31594835)

  • 1. Role of optimal cytoreduction in patients with dysgerminoma.
    Bandala-Jacques A; Estrada-Rivera F; Cantu D; Prada D; Montalvo-Esquivel G; González-Enciso A; Barquet-Munoz SA
    Int J Gynecol Cancer; 2019 Nov; 29(9):1405-1410. PubMed ID: 31594835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors.
    Turkmen O; Karalok A; Basaran D; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    J Adolesc Young Adult Oncol; 2017 Jun; 6(2):270-276. PubMed ID: 28085535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the surgical management of malignant ovarian germcell tumors.
    Nasioudis D; Mastroyannis SA; Latif NA; Ko EM
    Gynecol Oncol; 2020 Apr; 157(1):89-93. PubMed ID: 32008791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure dysgerminoma of the ovary: a review of 45 well staged cases.
    Ayhan A; Bildirici I; Günalp S; Yuce K
    Eur J Gynaecol Oncol; 2000; 21(1):98-101. PubMed ID: 10726633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors.
    Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
    Int J Gynecol Cancer; 2019 Mar; 29(3):554-559. PubMed ID: 30700566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival.
    Rajkumar S; Nath R; Lane G; Mehra G; Begum S; Sayasneh A
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():26-31. PubMed ID: 30639953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of rare ovarian tumors--possibilities of organ preservation].
    Grischke EM; Wallwiener D; Bastert G
    Zentralbl Gynakol; 1996; 118(6):322-5. PubMed ID: 8768007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors.
    Karalok A; Comert GK; Kilic C; Turkmen O; Kilic F; Basaran D; Boyraz G; Tekin ÖM; Turan T
    J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):461-466. PubMed ID: 31228608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors.
    Ertas IE; Taskin S; Goklu R; Bilgin M; Goc G; Yildirim Y; Ortac F
    J Obstet Gynaecol Res; 2014 Mar; 40(3):797-805. PubMed ID: 24320102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.